Understanding MOG antibody-associated disease with imaging and blood and spinal-fluid tests to guide care
Utilizing epidemiology, imaging and fluid biomarkers in MOG antibody-associated disease to inform prognosis, pathogenesis and therapeutics
['FUNDING_R01'] · MAYO CLINIC ROCHESTER · NIH-11295779
This project uses medical records, brain and spinal cord imaging, and blood and spinal-fluid tests to find markers that help predict outcomes and guide treatments for people with MOG antibody-associated disease.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAYO CLINIC ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-11295779 on ClinicalTrials.gov |
What this research studies
If you join, you may share medical records and give blood or spinal-fluid samples during attacks and at follow-up so researchers can study antibody levels and immune signals over time. You may have advanced brain and spinal cord imaging to look for features linked to damage or recovery. The team will combine data from population registries and their neuroimmunology lab's large datasets to map who gets MOGAD, when attacks occur, and how biology changes over time. The work aims to connect these findings to tests that predict relapse risk and to identify targets for new treatments.
Who could benefit from this research
Good fit: People diagnosed with MOG antibody-associated disease (MOGAD), including children and adults and especially those with recent attacks or available blood/CSF samples, would be ideal candidates.
Not a fit: People without MOG antibodies or with unrelated neurological conditions are unlikely to benefit directly from MOGAD-specific biomarkers or findings.
Why it matters
Potential benefit: If successful, this work could produce tests that help predict relapses, guide personalized treatment decisions, and point to new therapies for people with MOGAD.
How similar studies have performed: The team’s prior R01 cycle led to many publications and helped shape 2023 MOGAD diagnostic criteria, but prognostic biomarkers and proven treatments remain lacking.
Where this research is happening
ROCHESTER, UNITED STATES
- MAYO CLINIC ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FLANAGAN, EOIN P — MAYO CLINIC ROCHESTER
- Study coordinator: FLANAGAN, EOIN P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.